Peter Salzmann
Chief Executive Officer at IMMUNOVANT, INC.
Net worth: 34 M $ as of 31/03/2024
Profile
Peter Salzmann is currently the Chief Executive Officer & Director at Immunovant, Inc. He is also the Chief Executive Officer at IMVT Corp.
and a Director at Corbus Pharmaceuticals, Inc. Additionally, he serves as an Independent Director at Corbus Pharmaceuticals Holdings, Inc. and as a Director at Immunovant Sciences Ltd.
Previously, Dr. Salzmann worked at Eli Lilly & Co. from 2011 to 2019, where he held the position of Head-Immunology from 2013 to 2019.
He also worked at Eli Lilly Asia, Inc. from 2008 to 2010 as the Head-Marketing.
Dr. Salzmann's education includes an undergraduate degree from Northwestern University, an MBA from Stanford Graduate School of Business, and a doctorate from Pritzker School of Medicine.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
IMMUNOVANT INC
0.72% | 17/04/2024 | 1,052,879 ( 0.72% ) | 34 M $ | 31/03/2024 |
| 22/03/2024 | 0 ( -.--% ) | - $ | 31/03/2024 |
Peter Salzmann active positions
| Companies | Position | Start |
|---|---|---|
| CORBUS PHARMACEUTICALS HOLDINGS, INC. | Director/Board Member | 06/03/2020 |
| IMMUNOVANT, INC. | Chief Executive Officer | 01/06/2019 |
Corbus Pharmaceuticals, Inc.
 Corbus Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Corbus Pharmaceuticals, Inc. is engaged in biotechnology services. The company is headquartered in Norwood, MA. | Director/Board Member | - |
| IMVT Corp. | Chief Executive Officer | - |
Immunovant Sciences Ltd.
 Immunovant Sciences Ltd. BiotechnologyHealth Technology Part of Roivant Sciences Ltd., Immunovant Sciences Ltd. develops restorative therapies for autoimmune diseases. The private company is based in Hamilton, Bermuda. Immunovant Sciences was acquired by Health Sciences Acquisitions Corp. from Roivant Sciences Ltd. on December 19, 2019 for $863.06 million. | Director/Board Member | 01/10/2019 |
Former positions of Peter Salzmann
| Companies | Position | End |
|---|---|---|
| ELI LILLY AND COMPANY | Corporate Officer/Principal | 01/06/2019 |
| Eli Lilly Asia, Inc. | Sales & Marketing | 01/12/2010 |
Training of Peter Salzmann
| Northwestern University | Undergraduate Degree |
| Stanford Graduate School of Business | Masters Business Admin |
| Pritzker School of Medicine | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 3 |
|---|---|
| ELI LILLY AND COMPANY | Health Technology |
| CORBUS PHARMACEUTICALS HOLDINGS, INC. | Health Technology |
| IMMUNOVANT, INC. | Health Technology |
| Private companies | 4 |
|---|---|
Corbus Pharmaceuticals, Inc.
Corbus Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Corbus Pharmaceuticals, Inc. is engaged in biotechnology services. The company is headquartered in Norwood, MA. | Health Technology |
| Eli Lilly Asia, Inc. | |
Immunovant Sciences Ltd.
Immunovant Sciences Ltd. BiotechnologyHealth Technology Part of Roivant Sciences Ltd., Immunovant Sciences Ltd. develops restorative therapies for autoimmune diseases. The private company is based in Hamilton, Bermuda. Immunovant Sciences was acquired by Health Sciences Acquisitions Corp. from Roivant Sciences Ltd. on December 19, 2019 for $863.06 million. | Health Technology |
| IMVT Corp. |
- Stock Market
- Insiders
- Peter Salzmann